Professor Paul Glue's research focuses on clinical and basic science to investigate the pharmacology of drug treatments in psychiatry and the disease mechanisms of neurological and psychiatric disorders. He is also interested in psychopharmacology and the development of novel therapeutics for affective disorders. Biomarkers for anxiety and the technical aspects of clinical trial design, including trialing simulation and modeling are other areas of interest. He has published extensively, with more than 300 papers, book chapters and abstracts to his name.
Find out more about Professor Paul Glue’s research.
Publications
Gale, C., Glue, P., Guaiana, G., Coverdale, J., McMurdo, M., & Wilkinson, S. (2019). Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 33(5), 543-547. doi: 10.1177/0269881118822146
Thom, K., Lenagh-Glue, J., O'Brien, A. J., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2019). Service user, whānau and peer support workers' perceptions of advance directives for mental health. International Journal of Mental Health Nursing. Advance online publication. doi: 10.1111/inm.12637
Johari, N., Glue, P., & Barak, Y. (2019). Screaming behaviour in response to electroconvulsive treatment: Psychogeriatric note on a patient with Alzheimer's disease. Psychogeriatrics. Advance online publication. doi: 10.1111/psyg.12443
Neehoff, S., & Glue, P. (2019). Dissociation after ketamine dosing: Is the CADSS fit for purpose? Journal of Affective Disorders, 244, 239-240. doi: 10.1016/j.jad.2017.11.088
Ortiz, V. G., Glue, P., Somogyi, A. A., Martin, D., Alonzo, A., Rodgers, A., … Loo, C. K. (2019). A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression - the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 33(2), 260-261. doi: 10.1177/0269881118822147
Chapter in Book - Research
De Ridder, D., Manning, P., Cape, G., Vanneste, S., Langguth, B., & Glue, P. (2016). Pathophysiology-based neuromodulation for addictions: An overview. In V. R. Preedy (Ed.), Neuropathology of drug addictions and substance misuse (Vol. 1: Foundations of understanding, tobacco, alcohol, cannabinoids and opioids). (pp. 14-24). London: Elsevier. doi: 10.1016/B978-0-12-800213-1.00002-X
Dawson, J., Ellis, P., Glue, P., Goldsmith, D., Lenagh-Glue, J., & Smith, D. A. R. (2013). Mandatory second opinions on compulsory treatment. In J. Dawson & K. Gledhill (Eds.), New Zealand's Mental Health Act in practice. (pp. 229-246). Wellington, New Zealand: Victoria University Press.
Journal - Research Article
Gale, C., Glue, P., Guaiana, G., Coverdale, J., McMurdo, M., & Wilkinson, S. (2019). Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 33(5), 543-547. doi: 10.1177/0269881118822146
Thom, K., Lenagh-Glue, J., O'Brien, A. J., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2019). Service user, whānau and peer support workers' perceptions of advance directives for mental health. International Journal of Mental Health Nursing. Advance online publication. doi: 10.1111/inm.12637
Le Nedelec, M., Glue, P., Winter, H., Goulton, C., & Medlicott, N. J. (2018). The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats. Journal of Psychopharmacology. Advance online publication. doi: 10.1177/0269881118780013
Le Nedelec, M., Glue, P., Winter, H., Goulton, C., Broughton, L., & Medlicott, N. (2018). Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations. Drug Delivery & Translational Research, 8(3), 780-786. doi: 10.1007/s13346-017-0476-2
Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., … Loo, C. K. (2018). Repeated intranasal ketamine for treatment-resistant depression: The way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 32(4), 397-407. doi: 10.1177/0269881118760660
Shadli, S. M., Kawe, T., Martin, D., McNaughton, N., Neehoff, S., & Glue, P. (2018). Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. International Journal of Neuropsychopharmacology. Advance online publication. doi: 10.1093/ijnp/pyy032
Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018). Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. Journal of Psychopharmacology, 32(6), 663-667. doi: 10.1177/0269881118762073
Menkes, D. B., Glue, P., Gale, C., Lam, F., Hung, C.-T., & Hung, N. (2018). Steady-state clozapine and norclozapine pharmacokinetics in Maori and European patients. EBioMedicine, 27, 134-137. doi: 10.1016/j.ebiom.2017.11.030
Leitch, S., Glue, P., Gray, A. R., Greco, P., & Barak, Y. (2018). Comparison of psychosocial variables associated with loneliness in centenarian vs elderly populations in New Zealand. Jama Network Open, 1(6), e183880. doi: 10.1001/jamanetworkopen.2018.3880
Lenagh-Glue, J., O'Brien, A., Dawson, J., Thom, K., Potiki, J., Casey, H., & Glue, P. (2018). A MAP to mental health: The process of creating a collaborative advance preferences instrument. New Zealand Medical Journal, 131(1486), 18-26. Retrieved from https://www.nzma.org.nz/journal
Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017). Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1302-1305. doi: 10.1177/0269881117705089
George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D., … Glue, P., … Loo, C. K. (2017). Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. American Journal of Geriatric Psychiatry, 25(11), 1199-1209. doi: 10.1016/j.jagp.2017.06.007
Castle, C., Gray, A., Neehoff, S., & Glue, P. (2017). Effect of ketamine dose on self-rated dissociation in patients with treament refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1306-1311. doi: 10.1177/0269881117725685
Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., … Rodgers, A. (2016). Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 19(4), 1-15. doi: 10.1093/ijnp/pyv124
Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Hung, N., … Harland, S., … Friedhoff, L. (2016). Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clinical Pharmacology in Drug Development, 5(6), 460-468. doi: 10.1002/cpdd.254
Whigham, P. A., de Graaf, B., Srivastava, R., & Glue, P. (2016). Managing distance and covariate information with point-based clustering. BMC Medical Research Methodology, 16(1), 115. doi: 10.1186/s12874-016-0218-z
Shadli, S. M., Smith, M. J., Glue, P., & McNaughton, N. (2016). Testing an anxiety process biomarker: Generalisation from an auditory to a visual stimulus. Biological Psychology, 117, 50-55. doi: 10.1016/j.biopsycho.2016.02.011
French, J., Glue, P., Friedman, D., Almas, M., Yardi, N., Knapp, L., … Posner, H. B. (2016). Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. Neurology, 87(12), 1242-1249. doi: 10.1212/wnl.0000000000003118
Loo, C. K., Gálvez, V., O'Keefe, E., Mitchell, P. B., Hadzi-Pavlovic, D., Leyden, J., … Glue, P. (2016). Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 134(1), 48-56. doi: 10.1111/acps.12572
De Ridder, D., Vanneste, S., Gillett, G., Manning, P., Glue, P., & Langguth, B. (2016). Psychosurgery reduces uncertainty and increases free will? A review. Neuromodulation, 19, 239-248. doi: 10.1111/ner.12405
Courts, J., Maskill, V., Gray, A., & Glue, P. (2016). Signs and symptoms associated with synthetic cannabinoid toxicity: Systematic review. Australasian Psychiatry, 24(6), 598-601. doi: 10.1177/1039856216663733
Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Gray, A., Hung, N., … Harland, S., … Friedhoff, L. (2016). Switching opioid-dependent patients from methadone to morphine: Safety, tolerability, and methadone pharmacokinetics. Journal of Clinical Pharmacology, 56(8), 960-965. doi: 10.1002/jcph.704
Glue, P., Courts, J., Gray, A., & Patterson, T. (2016). Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey. New Zealand Medical Journal, 129(1433), 41-44. Retrieved from http://www.nzma.org.nz/journal
Forsyth, B., Machado, L., Jowett, T., Jakobi, H., Garbe, K., Winter, H., & Glue, P. (2016). Effects of low dose ibogaine on subjective mood state and psychological performance. Journal of Ethnopharmacology, 189, 10-13. doi: 10.1016/j.jep.2016.05.022
Glue, P., Courts, J., Gale, C., & Mason, E. (2015). Implementation of the 2013 Psychoactive Substances Act and mental health harms from synthetic cannabinoids. New Zealand Medical Journal, 128(1414). Retrieved from https://www.nzma.org.nz/journal
Glue, P., & Herbison, P. (2015). Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis. Australian & New Zealand Journal of Psychiatry, 49(12), 1215-1220. doi: 10.1177/0004867415614109
Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C.-T., & Friedhoff, L. (2015). Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 55(2), 189-194. doi: 10.1002/jcph.404
Glue, P., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Lenagh-Glue, Z., & Hung, C. T. (2015). Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology, 55(6), 680-687. doi: 10.1002/jcph.471
Shadli, S. M., Glue, P., McIntosh, J., & McNaughton, N. (2015). An improved human anxiety process biomarker: Characterization of frequency band, personality and pharmacology. Translational Psychiatry, 5, e699. doi: 10.1038/tp.2015.188
Dawson, J., Glue, P., Ellis, P. M., Lenagh-Glue, J., Goldsmith, D., & Smith, D. A. R. (2015). Lessons from export to New Zealand of the second opinion appointed doctor scheme. BJPsych Bulletin, 39(2), 69-73. doi: 10.1192/pb.bp.113.046540
Gupta, S. K., Kantesaria, B., & Glue, P. (2014). Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. Drug Discoveries & Therapeutics, 8(2), 89-95. doi: 10.5582/ddt.8.89
Lai, R., Katalinic, N., Glue, P., Somogyi, A. A., Mitchell, P. B., Leyden, J., … Loo, C. K. (2014). Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. World Journal of Psychiatry, 15(7), 579-584. doi: 10.3109/15622975.2014.922697
Shelker, W., Zaharic, T., Sijnja, B., & Glue, P. (2014). Influence of rural background and rural medical training on postgraduate medical training and location in New Zealand. New Zealand Medical Journal, 127(1403). Retrieved from http://www.nzma.org.nz/journal
Shelker, W., Poole, P., Bagg, W., Wood, I., & Glue, P. (2014). Postgraduation retention of medical students from Otago and Auckland medical programmes. New Zealand Medical Journal, 127(1388). Retrieved from http://www.nzma.org.nz/journal
Baby, M., Glue, P., & Carlyle, D. (2014). 'Violence is not part of our job': A thematic analysis of psychiatric mental health nurses' experiences of patient assaults from a New Zealand perspective. Issues in Mental Health Nursing, 35(9), 647-655. doi: 10.3109/01612840.2014.892552
Campbell, A., Ruffman, T., Murray, J. E., & Glue, P. (2014). Oxytocin improves emotion recognition for older males. Neurobiology of Aging, 35(10), 2246-2248. doi: 10.1016/j.neurobiolaging.2014.04.021
Dyke, J., Hendry, K., Hill, J., Schultz, M., Mason, E., & Glue, P. (2014). Management of a cluster of foreign body ingestion incidents in patients with borderline personality disorder. Open Journal of Psychiatry, 4, 99-103. doi: 10.4236/ojpsych.2014.42014
Lenagh-Glue, J., Glue, P., & Dawson, J. (2014). When the mandatory second opinion fails to approve compulsory treatment. Australasian Psychiatry, 22(4), 337-340. doi: 10.1177/1039856214537879
Alvarez-Grandi, S., Leon de la Barra, S., Seifert, A., & Glue, P. (2014). Electroconvulsive therapy use in Otago, New Zealand: A 10-year retrospective audit of patient-level treatment data. Australian & New Zealand Journal of Psychiatry, 48(6), 548-553. doi: 10.1177/0004867413514119
Patterson, T., Rapsey, C. M., & Glue, P. (2013). Systematic review of cognitive development across childhood in Down syndrome: Implications for treatment interventions. Journal of Intellectual Disability Research, 57(4), 306-318. doi: 10.1111/j.1365-2788.2012.01536.x
Gupta, S. K., Kantesaria, B., & Glue, P. (2013). Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discoveries & Therapeutics, 7(4), 158-163. doi: 10.5582/ddt.2013.v7.4.158
Chai, Y. K., Wheeler, Z., Herbison, P., Gale, C., & Glue, P. (2013). Factors associated with hospitalization of adult psychiatric patients: Cluster analysis. Australasian Psychiatry, 21(2), 141-146. doi: 10.1177/1039856213475682
McNaughton, N., Swart, C., Neo, P., Bates, V., & Glue, P. (2013). Anti-anxiety drugs reduce conflict-specific “theta”: A possible human anxiety-specific biomarker. Journal of Affective Disorders, 148(1), 104-111. doi: 10.1016/j.jad.2012.11.057
Katalinic, N., Lai, R., Somogyi, A., Mitchell, P. B., Glue, P., & Loo, C. K. (2013). Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Australian & New Zealand Journal of Psychiatry, 47(8), 710-727. doi: 10.1177/0004867413486842
Shelker, W., Herbison, P., Belton, A., & Glue, P. (2013). Factors related to postgraduate retention of medical graduates in New Zealand. New Zealand Medical Journal, 126(1371). Retrieved from http://www.nzma.org.nz/journal
Henry, M. E., Bolo, N. R., Zuo, C. S., Villafuerte, R. A., Cayetano, K., Glue, P., … Renshaw, P. F. (2013). Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrobial Agents & Chemotherapy, 57(11), 5271-5276. doi: 10.1128/AAC.00394-13
Glue, P., Al-Shaqsi, S., Hancock, D., Gale, C., Strong, B., & Schep, L. (2013). Hospitalisation associated with use of the synthetic cannabinoid K2. New Zealand Medical Journal, 126(1377). Retrieved from http://www.nzma.org.nz/journal
Grott Zanicotti, C., Perez, D., & Glue, P. (2012). Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. Journal of Palliative Medicine, 15(4), 400-403. doi: 10.1089/jpm.2011.0314
